ARLINGTON, Va., November 16, 2016 – The Radiation Oncology Institute (ROI) invites researchers to submit their work for its inaugural publication awards, which will recognize studies focused on the comparative value of radiation therapy (RT) in an effort to improve cancer outcomes while slowing the growth of health care spending. Proposals are due March 1, 2017, and finalists’ papers will be published in a special issue of Advances in Radiation Oncology in September 2017.
“As the emphasis on value in health care grows, so does the need for evidence demonstrating the great value radiation therapy can have in treating cancer,” said ROI President Deborah A. Kuban, MD, FASTRO. “ROI launched these awards to recognize and promote research that illustrates this value and its impact on patients, providers, payers and policymakers.”
Eligible projects include full-length manuscripts focused on the value of RT, such as studies that evaluate the effectiveness, complication profile and/or cost of various RT treatments, studies focused on specific clinical situations or patient populations and/or studies of the comparative effectiveness of RT compared to other therapies, such as surgery and chemotherapy.
Ten manuscripts will be selected for publication in a special, value-focused issue of Advances in Radiation Oncology, the open-access clinical research journal of the American Society for Radiation Oncology (ASTRO). All articles published in the special issue will have their open-access article processing fee, which is valued at $2,000 per recipient, paid directly by ROI. Additionally, one manuscript will receive the ROI Outstanding Article Award, which provides an additional $5,000 research grant to support ongoing work related to the published paper.
Eligible applicants include individuals from institutions and organizations in the radiation oncology community; individuals from institutions and organizations outside of the radiation oncology community who possess necessary qualifications for the specified research; and research consortia. Each manuscript will be evaluated through the Advances in Radiation Oncology peer-review process and then considered by at least two ROI reviewers and judged on its overall impact, significance, approach and innovation.
Submissions must be received by March 1, 2017, at http://ees.elsevier.com/advancesradonc/default.asp. Award winners will be announced in early September and recognized at the 2017 ASTRO Annual Meeting in San Diego.
All ROI research initiatives stem from findings of the National Radiation Oncology Research Needs Assessment conducted during the ROI’s formative years to determine the most pressing areas of need for research in radiation oncology. The ROI National Research Agenda underscores the importance of research to demonstrate the significant medical expertise and value that radiation oncology brings to cancer care throughout the world and includes six priorities: communication strategies to improve understanding of RT; safety and quality indicators for treatment; development of a radiation oncology registry; best practices for managing radiation toxicity; comparative effectiveness research in radiation oncology; and assessment of the value of RT relative to other cancer treatment modalities. Detailed information about the awards, selection process and evaluation criteria is available at www.roinstitute.org.
The Radiation Oncology Institute (ROI) is a nonprofit, 501(c)(3) foundation created in 2006 by the American Society for Radiation Oncology (ASTRO) Board of Directors to support research and education efforts around the world that heighten the critical role of radiation therapy in the treatment of cancer. ROI strategically funds research on new and existing radiation therapy treatments to identify links between best practices and improved outcomes, to evaluate the efficacy and cost-benefit of radiation therapy and to foster multi-institutional research in radiation oncology. For more information, visit www.roinstitute.org.